Sinovac Biotech Ltd.’s coronavirus vaccine cut in half the risk of developing symptomatic Covid-19 in a key Brazilian study, suggesting two doses of the shot is less potent than some other immunizations designed to tame the ongoing pandemic.
The study, which was posted online and hasn’t yet been reviewed by independent scientists, showed the vaccine was more effective at protecting against dangerous infections. None of those who received the CoronaVac injection developed severe disease.
The results of the trial involving 9,823 volunteers bolstered similar findings from a larger Brazilian study released last week that found a 50 per cent protection rate 14 days after the first dose.
The efficacy falls short of the results with mRNA vaccines from companies including Pfizer Inc., BioNTech SE and Moderna Inc., which have been shown to prevent about 94 per cent of infections.
The lower efficacy may be one reason some Chinese officials have floated the idea that the country’s vaccines may need to be given in combination with other shots.
Gao Fu, the director of China’s disease control center, said steps such as changing the amount of vaccine given, the amount of time between doses or the type of shot administered were all possible ways to boost the vaccines’ potency, according to the New York Times. He subsequently told the Global Times newspaper that his comments were misunderstood, and that increasing vaccine effectiveness is a universal challenge, the Times wrote.
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU